Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

SMC Update - February 2015

The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines.

Colestilan (BindRen®) has been rejected for the treatment of hyperphosphataemia in adult patients with chronic kidney disease (CKD) stage 5 receiving haemodialysis or peritoneal dialysis. Comparative date with others similar agents did not demonstrate non-inferiority conclusively. The manufacturer did not present a sufficiently robust clinical and economic analysis to gain acceptance.

Umeclidinium / Vilanterol (Anoro®) has been accepted for use as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease. Two randomised controlled studies demonstrated improved lung function compared with an inhaled long-acting muscarinic antagonist and indirect comparisons demonstrated comparable efficacy with similar drug combinations.

Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.

Share 'SMC Update - February 2015' on Email Share 'SMC Update - February 2015' on Delicious Share 'SMC Update - February 2015' on Digg Share 'SMC Update - February 2015' on Facebook Share 'SMC Update - February 2015' on Google+ Share 'SMC Update - February 2015' on reddit Share 'SMC Update - February 2015' on StumbleUpon Share 'SMC Update - February 2015' on Twitter

atomic-wealth

No Comments to “SMC Update - February 2015”

Leave a Comment

(required)

(required)


Prescribing Advice for GPs is powered by WordPress.
Subscribe for Free to our RSS or Atom Feeds for New Entries.
Akismet has protected Prescribing Advice for GPs from 789,515 spam comments.

atomic-wealth
fond-illness
summer